7 Types of Therapeutic Peptides and What Each One Does for Your Body

Introduction

Peptides have moved from the margins of sports medicine and anti-aging clinics into mainstream metabolic care — and for good reason. GLP-1 receptor agonists are now among the most-prescribed medications in the world. BPC-157 appears in nearly every conversation about injury recovery. Epithalon has a quietly devoted following in longevity research circles. Yet for most people searching these terms online, there's a fundamental gap: they know the name of a peptide, but not the category it belongs to — and that category determines everything about how it works, what it's appropriate for, and what the evidence actually supports.

Therapeutic peptides are short chains of amino acids — typically between 2 and 50 units long — that function as biological signals rather than structural material. They tell cells what to do. And because different peptide categories signal to entirely different systems, conflating them is a bit like assuming all medications work the same way because they come in capsule form.

This article breaks the field into seven categories, classified by mechanism and biological target. Each type has a distinct role in the body, a distinct clinical evidence base, and a distinct set of questions you should be asking before you or your clinician consider it.

What makes a peptide "therapeutic"? A peptide is any molecule composed of 2–50 amino acids bonded in sequence. It becomes therapeutic when it's applied with clinical or functional intent — to regulate, restore, or support a specific physiological system. This distinguishes therapeutic peptides from dietary protein (which your body breaks down into amino acids for fuel and structure) and from larger protein molecules like antibodies (which are too large to act as direct cellular signals in the same way). Some therapeutic peptides are FDA-approved drugs; others are research compounds; and some sit in a regulatory grey area that is actively shifting. Understanding which category a peptide belongs to is the first step in understanding which of those buckets it falls into.

The 7 Types of Therapeutic Peptides

1. GLP-1 Receptor Agonists — The Metabolic Regulators Behind Today's Weight Loss Drugs

What they are: Glucagon-like peptide-1 (GLP-1) agonists are synthetic analogues of a hormone your intestinal L-cells release naturally after eating. They mimic that hormone's signaling function — but with a significantly longer half-life than the version your body produces.

How they work: GLP-1 receptors are distributed across the pancreas, hypothalamus, vagus nerve, and gut. When activated, these receptors simultaneously stimulate insulin secretion in response to glucose, suppress glucagon release (which would otherwise raise blood sugar), slow gastric emptying, and relay satiety signals to the brain's appetite-regulating centres. The result is a coordinated metabolic response — not a single targeted effect, which is part of why this class has been clinically transformative. Drucker's foundational work on incretin biology established much of this signaling architecture in 2006, and the field has moved quickly since.

Body effects: Improved glycaemic control, reduced appetite and caloric intake, meaningful weight reduction (15–21% of body weight in clinical trials of semaglutide), and demonstrated cardiovascular risk reduction in people with type 2 diabetes, as confirmed in the landmark SUSTAIN-6 trial.

Clinical examples: Semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), tirzepatide (Mounjaro, Zepbound — a dual GIP/GLP-1 agonist).

Most relevant for: Adults managing type 2 diabetes, insulin resistance, obesity, or metabolic syndrome with cardiovascular risk factors.

What to read next: If you're already on a GLP-1 or considering one, see Top 10 Questions to Ask Your Doctor About GLP-1 Lab Work — monitoring your labs correctly while on this class of medication matters more than most prescribers discuss at the point of prescription.

2. Growth Hormone Secretagogues (GHS) — The Regeneration and Body Composition Category

What they are: Growth hormone secretagogues are peptides that stimulate the pituitary gland to release growth hormone (GH) endogenously — an important distinction from synthetic HGH injections, which bypass pituitary regulation entirely and carry a different risk profile.

How they work: GHS peptides act on two receptor systems. GHRH analogues (like sermorelin and CJC-1295) bind growth hormone-releasing hormone receptors to amplify the natural GH pulse. Ghrelin analogues (like ipamorelin) bind ghrelin receptors, achieving a similar effect through a different pathway. MK-677 (ibutamoren) is a non-peptide oral secretagogue that mimics ghrelin receptor activity. The clinical appeal is that these compounds work with the body's existing pulsatile GH release patterns rather than overriding them. A 1998 study by Raun et al. in the European Journal of Endocrinology remains one of the most-cited characterisations of ipamorelin's selective GH-releasing activity — notably, it stimulates GH without the cortisol and prolactin spikes associated with earlier secretagogue compounds.

Body effects: Preservation of lean muscle mass, improved fat metabolism, accelerated tissue recovery, enhanced sleep quality (GH is primarily released during slow-wave sleep), and modest improvements in bone mineral density in older adults.

Clinical examples: Sermorelin, CJC-1295, ipamorelin, tesamorelin (FDA-approved for HIV-associated lipodystrophy), MK-677.

Most relevant for: Adults over 35 experiencing age-related GH decline, those in supervised body composition or longevity protocols, and people with documented GH deficiency.

3. Antimicrobial Peptides (AMPs) — The Body's Built-In Defence Layer

What they are: Antimicrobial peptides are among the oldest components of innate immunity. Your epithelial cells, immune cells, and mucous membranes produce them constantly — they are your body's first-line molecular response to microbial invasion, functioning before adaptive immunity has time to mount a response.

How they work: Most AMPs carry a net positive charge that allows them to interact electrostatically with the negatively charged membranes of bacteria, fungi, and enveloped viruses. Rather than binding to a specific receptor (the mechanism most antibiotics use), AMPs physically disrupt the structural integrity of microbial membranes — a property that makes resistance significantly harder to develop. Michael Zasloff's 2002 paper in Nature is the landmark review on this mechanism and remains essential reading for understanding why AMPs have attracted serious antibiotic-resistance research investment.

Body effects: Direct pathogen killing, modulation of the inflammatory response at wound sites, anti-biofilm activity (biofilms are how chronic infections persist), and stimulation of wound healing through downstream signalling.

Clinical examples: Human beta-defensins, LL-37 (the only known human cathelicidin), pexiganan (synthetic AMP in wound care trials), magainin analogues.

Most relevant for: People with chronic skin or mucosal infections, compromised immunity, or interest in next-generation antimicrobials. Note that most therapeutic AMP applications are still in clinical development — this is an active and promising area, not yet a mainstream clinical tool outside specific wound care contexts.

4. Tissue Repair Peptides — The Healing and Recovery Category

What they are: This category covers peptides that accelerate tissue regeneration, reduce localised inflammation, and support structural repair across multiple tissue types — muscle, tendon, gut lining, and neural tissue among them.

How they work: The best-characterised example is BPC-157 (Body Protection Compound-157), a 15-amino-acid sequence derived from a protein found in gastric juice. It upregulates growth factor expression (particularly VEGF, supporting new blood vessel formation at injury sites), modulates nitric oxide pathways, and appears to influence the gut-brain axis. Sikiric et al.'s 2016 review in Current Neuropharmacology provides a thorough summary of the preclinical evidence base, which is extensive in animal models. TB-500 (Thymosin Beta-4 synthetic fragment) operates through a different mechanism — it binds to actin to promote cell migration and differentiation at injury sites. Goldstein et al. (2012) detail its regenerative applications across cardiac, neural, and corneal tissue in the Expert Opinion on Biological Therapy.

Body effects: Accelerated tendon and muscle healing, gut mucosal repair, reduced inflammatory cytokine activity, and potential neuroprotective effects in neural injury.

Clinical examples: BPC-157, TB-500, GHK-Cu (a copper-binding tripeptide with significant skin and wound healing evidence), KPV (an anti-inflammatory tripeptide under investigation for IBD).

Most relevant for: Athletes with tendon or muscle injuries, people with gut permeability or inflammatory bowel conditions, and those in post-surgical recovery.

Important caveat: The human clinical trial evidence for BPC-157 and TB-500 specifically remains limited. The preclinical data is compelling; the clinical data has not yet caught up. Anyone considering these compounds should understand this distinction clearly — and the FDA's evolving stance on compounded peptides is relevant context.

5. Neuropeptides — The Brain-Body Signalling Category

What they are: Neuropeptides are synthesised in neurons and glial cells and act as neuromodulators — they don't transmit signals the way classical neurotransmitters (serotonin, dopamine) do, but they reshape how neurons respond to those signals. This modulatory role gives neuropeptides an outsized influence on mood, cognition, pain perception, appetite, and stress regulation.

How they work: Most neuropeptides operate through G-protein coupled receptors and can function either within the CNS or peripherally through neuroendocrine pathways. Some, like oxytocin and vasopressin, are produced in the hypothalamus and released systemically. Others, like the synthetic peptides Selank and Semax (developed through Russian neuropsychiatric research), appear to modulate BDNF (brain-derived neurotrophic factor) expression and GABAergic tone. MacDonald and MacDonald's 2010 systematic review in the Harvard Review of Psychiatry covers oxytocin's prosocial and anxiolytic effects across multiple human trial populations.

Body effects: Mood stabilisation, anxiety reduction, improved cognitive performance under stress, altered pain sensitivity, and appetite modulation.

Clinical examples: Oxytocin (therapeutically used in obstetrics and under investigation for autism spectrum disorder and social anxiety), Selank, Semax, Dihexa (nootropic, very early-stage), Substance P (pain signalling).

Most relevant for: People managing anxiety, stress-related cognitive disruption, chronic pain, or those exploring evidence-based nootropic protocols.

6. Peptide Hormones — The Endocrine Regulators You Already Know

What they are: This is the largest and most clinically established peptide category — and the one most people have already interacted with medically, often without realising it. Peptide hormones are naturally occurring signalling molecules produced by endocrine glands; they govern virtually every major physiological system.

How they work: Because peptide hormones are hydrophilic (water-soluble), they can't cross cell membranes directly. Instead, they bind to surface receptors and trigger intracellular signalling cascades from the outside. Insulin, for example, binds its receptor on muscle and fat cells, initiating the GLUT4 transporter translocation that allows glucose to enter the cell. This receptor-mediated mechanism gives peptide hormones a high degree of specificity — they act where their receptors are expressed, and nowhere else.

Body effects: Glucose metabolism (insulin), thyroid regulation (TSH, TRH), reproductive function (LH, FSH, hCG), stress response (ACTH, CRH), growth and tissue maintenance (GH), and fluid balance (ADH/vasopressin).

Clinical examples: Insulin (diabetes), synthetic oxytocin (labour induction and postpartum haemorrhage), desmopressin (diabetes insipidus and nocturnal enuresis), hCG (fertility), vasopressin (septic shock).

Historical context: Insulin was the first therapeutic peptide to enter clinical use — Banting and Best's 1921 work established the entire field. That historical grounding matters: it's a reminder that peptide therapeutics have been central to medicine for over a century, and GLP-1 agonists are an evolution of this lineage, not a departure from it.

Most relevant for: This category is relevant to almost everyone. If you take insulin, thyroid medication, or have undergone fertility treatment, you have engaged with therapeutic peptide hormones.

7. Peptide Bioregulators (Cytomedins) — The Longevity and Organ-Specific Restoration Category

What they are: Peptide bioregulators are short, tissue-specific peptides — typically just 2–4 amino acids — originally isolated from organ tissue extracts. They represent the most niche and perhaps most intellectually provocative category on this list.

How they work: The proposed mechanism, developed over four decades by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, is that these ultra-short peptides interact directly with DNA regulatory regions to influence gene expression in specific organ types. The organ-specificity is the distinguishing feature: thymus-derived peptides act on immune tissue, pineal-derived peptides on circadian and endocrine function, retinal peptides on ocular tissue. Khavinson et al.'s published research on Epithalon — a synthetic tetrapeptide — includes data on telomerase activation and telomere elongation in human cell cultures, which has drawn longevity researchers' attention despite the preliminary nature of the human data. Separately, Epithalon has been studied in the context of cancer incidence in long-term animal cohorts, with some intriguing results that warrant further controlled investigation.

Body effects: Organ-specific cellular restoration, immune system rebalancing (Thymalin), circadian rhythm and sleep regulation (Epithalon), cardiovascular tissue support (Vesugen), and neural tissue regeneration (Cortagen). Some studies suggest modest but statistically significant increases in survival in older populations, though the evidence base here is predominantly from the Russian literature and has not been extensively replicated in Western academic contexts.

Clinical examples: Epithalon (pineal, telomere research), Thymalin (thymus/immune), Vesugen (cardiovascular), Cortagen (neural), Vilon (immune), Retinalamin (retinal).

Most relevant for: Adults in structured longevity protocols, those with age-related organ decline, or people working with integrative medicine clinicians who are monitoring biological age markers. If biological age testing is part of your framework, see Biological Age Testing in 2026: The Complete Guide to Longevity Panels for context on how to pair biomarker data with any longevity-focused protocol.

Quick Reference: All 7 Therapeutic Peptide Types at a Glance

What to Know Before Exploring Therapeutic Peptides

This field moves fast — and the regulatory and safety landscape shifts with it. A few important distinctions worth internalising:

FDA-approved vs. compounded vs. research-use compound. Insulin and GLP-1 agonists have gone through the full clinical trial pipeline. Compounds like BPC-157 and TB-500 are being reviewed under evolving compounding pharmacy frameworks. And some peptides are sold strictly for research purposes, meaning they have not been evaluated for safety or efficacy in humans under controlled conditions. Understanding which category a specific peptide falls into before considering it is not optional — it's foundational. The FDA's 2026 peptide advisory process is directly relevant here.

Dosing and sourcing are not interchangeable across suppliers. Peptide purity and concentration vary significantly depending on the manufacturer. This is especially relevant for compounds obtained outside a licensed compounding pharmacy or clinical setting.

Your metabolic baseline determines your response. A person with well-regulated insulin signalling will respond to a GLP-1 agonist very differently from someone with significant insulin resistance. Bioregulatory peptides, similarly, may produce different outcomes depending on your current inflammatory load, hormonal status, and organ function. This is why lab work before starting any peptide protocol is not bureaucratic box-ticking — it is how you establish the biological context that determines whether a given compound is likely to help, have no effect, or cause an unintended shift. 8 Reasons to Get Lab Work Before Starting Any Weight Loss Program covers this logic in depth, and it applies beyond weight loss to any metabolic intervention.

Work with a clinician who understands the mechanism, not just the molecule. Category matters because mechanism matters. A clinician who understands that BPC-157 and semaglutide are both "peptides" but operate through entirely different systems — with entirely different evidence bases and regulatory contexts — is in a position to counsel you accurately. One who treats them as interchangeable is not.

Frequently Asked Questions

What are the main types of therapeutic peptides? 

The seven primary categories are: GLP-1 receptor agonists (metabolic regulation and weight management), growth hormone secretagogues (body composition and regeneration), antimicrobial peptides (immune defence and infection control), tissue repair peptides (healing and recovery), neuropeptides (brain-body signalling), peptide hormones (systemic endocrine regulation), and peptide bioregulators (organ-specific longevity applications). Each category acts through a distinct mechanism and targets a different physiological system.

Is GLP-1 a type of therapeutic peptide? 

Yes. GLP-1 receptor agonists are synthetic peptides that mimic the action of a naturally occurring gut hormone. Semaglutide, liraglutide, and tirzepatide all belong to this peptide category. They work by binding GLP-1 receptors in the pancreas, brain, and gut to regulate blood sugar, suppress appetite, and slow gastric emptying.

What is the difference between peptide hormones and other therapeutic peptides? 

Peptide hormones are a subcategory of therapeutic peptides — they are naturally produced by endocrine glands and act systemically through surface receptors on target cells. Other therapeutic peptide categories (like tissue repair peptides or neuropeptides) may be synthetic, partially derived from natural sequences, or function through mechanisms that are entirely outside the endocrine system.

Are growth hormone secretagogue peptides the same as HGH? 

No. Growth hormone secretagogues stimulate your pituitary gland to produce and release its own growth hormone — they work within the body's existing regulatory architecture. Synthetic HGH (human growth hormone) bypasses pituitary control entirely and delivers GH directly. The risk profiles and regulatory frameworks for these two approaches are different.

Which type of therapeutic peptide is best for metabolic health? 

That depends entirely on which aspect of metabolic function you are addressing and what your underlying labs reveal. GLP-1 agonists have the strongest evidence base for glucose regulation, insulin resistance, and weight-related metabolic dysfunction. Growth hormone secretagogues support body composition and metabolic rate. Peptide hormones like insulin are non-negotiable for specific endocrine conditions. There is no universal answer — which is precisely why a clinical assessment that includes lab work is the necessary first step.

Are therapeutic peptides safe? 

Safety varies significantly by peptide type, clinical context, individual metabolic status, and source. FDA-approved peptide drugs (insulin, GLP-1 agonists) have established safety profiles from large-scale trials. Compounded and research-use peptides have more limited human safety data. Sourcing from reputable, licensed compounding pharmacies and working with a clinician who monitors your response through lab work is the standard of care for any peptide protocol.

Meto's Perspective: Why Metabolic Context Comes Before Any Peptide Decision

The conversation around therapeutic peptides has, in many corners of the internet, outrun the clinical evidence. That's not a reason to dismiss the category — it's a reason to be more precise about it.

At Meto, we think about peptide therapy through a metabolic lens, and that lens starts with data. Before anyone on our platform considers a peptide intervention — whether that's a GLP-1 agonist for insulin resistance, a GHS peptide for body composition, or a bioregulator for longevity — we want to understand what their metabolic baseline looks like. That means knowing their fasting insulin and glucose, their inflammatory markers, their hormone panel, and their liver and thyroid function. Peptides are biological signals, and signals land differently depending on the receptor environment they're entering.

This is also where the most common failure mode in self-directed peptide protocols happens: people optimise for the peptide without characterising the system. They add semaglutide without knowing whether their insulin resistance is driven by cortisol dysregulation, liver dysfunction, or a simple dietary pattern. They add growth hormone secretagogues without checking IGF-1 or existing GH status. The peptide becomes a layer on top of an unresolved metabolic picture — and the results reflect that.

Our approach is different. Clinician-led, lab-grounded, and specific to what your biology is actually doing — not what your symptoms suggest it might be doing.

Ready to understand your metabolic baseline before making any peptide decision?

Book a Meto Metabolic Consult →

Our clinicians will review your symptoms, order the right labs, and give you a clear picture of where your metabolic system stands — before you add anything to it. If peptide therapy is appropriate for your situation, you'll know which type, why, and what to monitor.

Or, if you prefer to start with your labs, explore our Comprehensive Metabolic Panel ($199) or Longevity Panel ($399) — both include a clinician review and next-step recommendations.

This article is for informational purposes only and does not constitute medical advice. Therapeutic peptides vary significantly in their regulatory status, evidence base, and appropriateness for individual patients. Consult a licensed clinician before initiating any peptide protocol.

Related reading:

• Top 10 Questions to Ask Your Doctor About GLP-1 Lab Work
• FDA July 2026 Peptide Meeting: What Patients Need to Know
• 9 Essential Amino Acids Explained: Benefits, Functions & Food Sources
• How Amino Acids Control Your Hormones: The Protein–Endocrine Connection Explained
• Biological Age Testing in 2026: The Complete Guide to Longevity Panels
• 8 Reasons to Get Lab Work Before Starting Any Weight Loss Program